Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of BLX-0871 in Healthy Adults
NCT07140081Phase 1Not yet recruiting
- Sponsor
- Biolexis Therapeutics
- Start
- Sep 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BLX-0871 in type 2 diabetes mellitus (T2DM) and obesity (5 arms), sponsored by Biolexis Therapeutics. Primary endpoints: Number of participants who experienced Adverse Events (AEs), Number of participants who experienced Serious Adverse Events (SAEs) and 1 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
BLX-0871
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07140081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07140081.